Press Releases
- Active Biotech announces outcome of the Company’s rights issue
- Active Biotech enters into collaboration agreement for clinical ocular biodistribution study with laquinimod
- Active Biotech’s nomination committee appointed
- Lead Principal Investigator Rebekka Schneider-Kramann presents the clinical plan and positioning of tasquinimod in myelofibrosis
- Management and members of the board of directors have subscribed for shares in Active Biotech’s ongoing rights issue